191 related articles for article (PubMed ID: 38309550)
1. Crosstalk between m6A modification and non-coding RNAs in HCC.
Qiu Z; Yuan X; Wang X; Liu S
Cell Signal; 2024 May; 117():111076. PubMed ID: 38309550
[TBL] [Abstract][Full Text] [Related]
2. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.
Qin S; Mao Y; Chen X; Xiao J; Qin Y; Zhao L
Int J Biol Sci; 2021; 17(12):3059-3079. PubMed ID: 34421350
[TBL] [Abstract][Full Text] [Related]
3. The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer.
Xu X; Zhao J; Yang M; Han L; Yuan X; Chi W; Jiang J
Eur J Med Res; 2023 Nov; 28(1):475. PubMed ID: 37915103
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
Liu X; Xie X; Sui C; Liu X; Song M; Luo Q; Zhan P; Feng J; Liu J
Int J Cancer; 2024 Jun; 154(11):1877-1889. PubMed ID: 38429857
[TBL] [Abstract][Full Text] [Related]
5. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
[TBL] [Abstract][Full Text] [Related]
7. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
Yu ZL; Zhu ZM
Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
[TBL] [Abstract][Full Text] [Related]
9. Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.
Shi Q; Chu Q; Zeng Y; Yuan X; Wang J; Zhang Y; Xue C; Li L
Cell Commun Signal; 2023 Dec; 21(1):359. PubMed ID: 38111040
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment.
Wang D; Han Y; Peng L; Huang T; He X; Wang J; Ou C
Int J Biol Sci; 2023; 19(7):2198-2219. PubMed ID: 37151887
[TBL] [Abstract][Full Text] [Related]
11. The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.
Qin S; Mao Y; Wang H; Duan Y; Zhao L
Int J Biol Sci; 2021; 17(11):2718-2736. PubMed ID: 34345203
[TBL] [Abstract][Full Text] [Related]
12. KIAA1429 facilitates metastasis via m6A-YTHDC1-dependent RND3 down-regulation in hepatocellular carcinoma cells.
Shan M; Liu D; Sun L; Yang M; He M; Zhang Y; Xiang L; Lu L; He H; Niu D; Chen L; Li S; Chen A; He F; Wang Y; Lian J
Cancer Lett; 2024 Mar; 584():216598. PubMed ID: 38224863
[TBL] [Abstract][Full Text] [Related]
13. Research Progress on Long Noncoding RNAs and N6-Methyladenosine in Hepatocellular Carcinoma.
Zhang W; Wu W; Meng Q; Yang L; Yuan J; Tian Z; Ding R; Zhang X; Wang J; Tao K
Front Oncol; 2022; 12():907399. PubMed ID: 35936671
[TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
15. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy.
Hou W; Bonkovsky HL
World J Gastroenterol; 2013 Nov; 19(44):7836-45. PubMed ID: 24307777
[TBL] [Abstract][Full Text] [Related]
16. Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.
Zhang C; Dai D; Zhang W; Yang W; Guo Y; Wei Q
J Gastroenterol Hepatol; 2022 Nov; 37(11):2039-2050. PubMed ID: 36066844
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL
Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740
[TBL] [Abstract][Full Text] [Related]
18. Dynamic m6A-ncRNAs association and their impact on cancer pathogenesis, immune regulation and therapeutic response.
Yan Y; Peng J; Liang Q; Ren X; Cai Y; Peng B; Chen X; Wang X; Yi Q; Xu Z
Genes Dis; 2023 Jan; 10(1):135-150. PubMed ID: 37013031
[TBL] [Abstract][Full Text] [Related]
19. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
Fang Q; Chen H
Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
[TBL] [Abstract][Full Text] [Related]
20. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
